Atopic Dermatitis

Medical experts review the data on the use of oral JAK inhibitors for maintenance and rescue treatments in atopic dermatitis.

In this cohort study, the drug survival rates of methotrexate, cyclosporine A, and dupilumab for adolescents with eczema were assessed along with reasons for discontinuation.

In this single center analysis, investigators highlighted results of dupilumab treatment after 3 years among patients with moderate-to-severe eczema.

Medical experts discuss how often patients with atopic dermatitis request treatment breaks, their monitoring approach during these breaks, and how to educate and counsel patients about treatment breaks and rescue treatments, including identifying suitable candidates.

Medical experts rate dermatologists’ comfort with switching to JAK inhibitors and describe how frequently to switch patients from biologics to JAK inhibitors, including their treatment strategy for this population.

These data highlight barriers to pediatric treatments for eczema, providing potential strategies for caregivers and patients for adherence improvement.

Looking to the future of atopic dermatitis treatment, the panel discusses ongoing research and promising emerging therapies.

Medical experts discuss disease control with abrocitinib or upadacitinib in patients previously taking dupilumab and explain the circumstances under which they would switch a patient to a JAK inhibitor.

Medical experts discuss the importance of setting treatment expectations and maintaining dialogue with patients about targets and explain how to decide on a new treatment when switching.

New data reports a notably heightened risk of atopic dermatitis in patients with prurigo nodulais compared with a control cohort.

A new post-hoc analysis has also revealed improvements in quality of life in patients’ caregivers.

An EADV 2024 study suggests dupilumab use during pregnancy is generally safe and may lower risks of preterm labor, gestational hypertension, and diabetes.

Further research is needed to understand the mechanism behind the link as antibiotic exposure is often necessary in care.

Ruxolitinib cream offers an effective nonsteroidal treatment for mild to moderate atopic dermatitis, with proven efficacy and safety for sensitive skin areas.

Medical experts evaluate the role of biologics in atopic dermatitis, including their efficacy and safety, and discuss reasons for switching between systemic treatments.

Medical experts discuss the significance of speed in achieving itch relief when choosing a treatment for atopic dermatitis.

Focusing on clinical scenarios, experts on atopic dermatitis discuss how their treatment approaches vary depending on patient-specific factors.

Dermatologists outline the role of targeted therapies and JAK inhibitors in the treatment of patients with atopic dermatitis.

In this interview at EADV, Thaçi was asked to highlight his team’s recent data from the ARCADIA trial program on nemolizumab for patients with eczema.

The 9-month interim results of the TRACE study were presented at EADV 2024, highlighting tralokinumab’s efficacy in a subset of patients with eczema impacting the head and neck areas.

This interview with Alexis features his reaction to the approval of lebrikizumab for eczema and its significance.

The DELTA trial results on delgocitinib cream as a topical option for CHE were presented at the EADV Congress 2024.

Temtokibart showed similar efficacy to dupilumab in treating moderate-to-severe atopic dermatitis, with faster skin hydration improvements in a phase 2a trial.

These new data on treatment of atopic dermatitis and prurigo nodularis were presented by Galderma at the European Academy of Dermatology & Venereology Congress.

These new findings were released by Eli Lilly and presented at the European Academy of Dermatology & Venereology Congress.